Statins improve asthma symptoms by suppressing inflammation: a meta-analysis based on RCTs

Q.-X. Zhang, H.-F. Zhang, X.-T. Lu, J. Zhao, Q.-X. Xu

Division of Respiratory Medicine, Digestive Internal Medicine, The First People’s Hospital of Fuyang Hangzhou, Hangzhou, China. xuqinxing@yeah.net

---

• Internal Medicine
• Respiratory Medicine

OBJECTIVE: Asthma is a chronic airway inflammatory disease caused by high infiltration of multiple inflammatory cells and factors in airway tissues. Statins may inhibit inflammation, hence improve asthma symptoms. This meta-analysis aimed to assess the efficacy of statins in the treatment of asthma patients.

MATERIALS AND METHODS: We searched in PubMed, OVID, Cochrane Library, and Web of Science databases using the following key words: “statin”, “atorvastatin”, “simvastatin”, “pravastatin”, “rosuvastatin”, “pitavastatin”, “fluvastatin”, and “asthma”. The effects of statins on function, serum biomarkers, sputum mediators, and serum biochemical markers were analyzed from the identified studies.

RESULTS: Twelve articles (613 participants) were included in the meta-analysis. Results showed that statins significantly improved asthma symptoms (ACQ score: MD: -0.43, 95% CI: -0.47 – -0.38, p<0.01; ACT score: MD: 1.96, 95% CI: 1.26-2.67, p<0.01). Furthermore, statins significantly reduced serum hsCRP (MD: -0.50, p=0.02) and cholesterol (MD: -32.76, p<0.01) levels and the proportion of sputum eosinophils (MD: -1.25, p<0.01) and IL6 levels (MD: -64.56, p=0.04) in sputum. However, lung function was not significantly different between the statin and placebo treatment groups.

CONCLUSIONS: Although statins did not change the lung function in patients with asthma, they improved asthma symptoms and reduced the serum hsCRP, sputum eosinophil ratio, and IL6 levels.

Free PDF Download